Feature | Cath Lab | March 06, 2013

The National Average for D2B Times

A recent review of data from the CathPCI Registry

Stemi lesion as seen on angiography

A STEMI lesion being treated in the cath lab.

A recent review of data from the CathPCI Registry, part of the American College of Cardiology’s (ACC) National Cardiovascular Data Registry (NCDR), offers some insight into average, real-world D2B times.[1] For STEMI patients who arrived at an angioplasty-capable hospital, the average time from hospital arrival to treatment was 64.5 minutes. For patients requiring transfer to another hospital, the average time from arrival at the first hospital to treatment was 121 minutes.  

The ACC 2013 STEMI guidelines estimated that almost 90 percent of patients presenting to a hospital with PCI capability and without a clinical reason for delay have a D2B time of about 90 minutes.[2] Some centers have implemented protocols and technology to reduce this to much faster times. In addition, with improvements in timeliness of care across the country, racial disparities in reperfusion times have been reduced significantly, the guidleines state.

The guidelines found that for STEMI patients reported by hospitals to the Centers for Medicare and Medicaid Services, median D2B times fell from 96 minutes in the year ending Dec. 31, 2005, to 64 minutes in the three quarters ending Sept. 30, 2010. This decline was accompanied by an increase in the percentage of patients with D2B times <90 minutes, from 44.2 to 91.4 percent. However, despite substantial improvements in D2B times, evidence that these efforts have translated into reduced mortality rates is lacking, the authors found. The absence of demonstrated benefit may relate to reduced power to show change in survival in a population with a relatively low mortality rate, improved early survival of higher-risk patients and changing STEMI demographics.  The guideline authors said these findings support the goal of comprehensive efforts to improve all aspects of acute myocardial infaction care to improve survival rates.

To read more on how to lower door-to-balloon times, read the story linked here.

 

Related Content on Reducing D2B and Patient Survival

Improving Cardiogenic Shock Survival With New Protocols

New Report Highlights National Trends in Heart Disease Treatments

5 Ways to Reduce Door to Balloon Time

Seeking Treatment Earlier May Improve Heart Attack Outcomes

Most Innovative Heart Centers: The Aspirus Heart & Vascular Institute

 

References:

1. Gregory Dehmer, Douglas Weaver, Matthew T. Roe, et al. “A Contemporary View of Diagnostic Cardiac Catheterization and Percutaneous Coronary Intervention in the United States: A Report From the CathPCI Registry of the National Cardiovascular Data Registry, 2010 Through June 2011.” J Am Coll Cardiol. 2012;60(20): 2017-2031.

2. Patrick O’Gara, Fredrick Kushner, Deborah Ascheim, et al. “2013 ACCF/AHA Guideline for Management of ST-Elevation Myocardial Infarction.” JACC Vol. 61, No. 4, Jan. 2013.

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init